We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Simple Blood Test Predicts Neuroendocrine Tumor Response to Radiopharmaceutical Therapy

By LabMedica International staff writers
Posted on 11 Apr 2023
Print article
Image: Blood-based biomarkers can accurately predict neuroendocrine tumor response to radiopharmaceutical therapy (Photo courtesy of Freepik)
Image: Blood-based biomarkers can accurately predict neuroendocrine tumor response to radiopharmaceutical therapy (Photo courtesy of Freepik)

Biomarkers have been employed to forecast treatment outcomes for breast, prostate, and other types of cancer, although no objective methods currently exist for predicting the success of radiopharmaceutical therapy for neuroendocrine tumors. Now, a new study has revealed that a simple blood test can supply doctors with crucial information to ascertain if peptide receptor radionuclide therapy (PRRT) is likely to be effective in patients with neuroendocrine cancer. The blood-based biomarker PPQ can accurately predict PRRT responsiveness in 96% of patients, and changes in another biomarker, NETest, correlate with PRRT response in 90% of cases.

Previously, a group of nuclear medicine physicians at Memorial Sloan Kettering Cancer Center (MSK, New York, NY, USA) had introduced the blood-based biomarkers PPQ and NETest as indicators for the success of PRRT treatment. In this new study, the team aimed to validate the significance of PPQ and NETest in predicting and monitoring PRRT response. The new study included 67 patients with somatostatin receptor-positive gastroenteropancreatic and lung neuroendocrine tumors, all of whom had metastatic disease and prior treatments. The participants submitted blood samples before each PRRT cycle and during follow-up. PPQ was scored as either positive (likely to respond) or negative (unlikely to respond), while NETest was measured on a scale of zero to 100, with 20 being the upper limit of normality.

Of the 67 patients, 40 were classified as PPQ+ and 39 of them (98%) responded to PRRT. Among the 27 PPQ- patients, 25 experienced disease progression despite PRRT. The overall predictive accuracy of PPQ was 96%. Prior to PRRT therapy, all patients exhibited elevated NETest levels. In PRRT responders, baseline NETest levels were 67, decreasing by 37% after treatment. For non-responders, baseline NETest levels were 44, which rose by 76% during follow-up. NETest's accuracy in determining PRRT response was 90%.

“The results of this study demonstrate that not all tumors are created equal; some are more prone to respond to PRRT, and some are less susceptible to radiopharmaceutical therapy,” said Lisa Bodei, MD, PhD, nuclear medicine physician at Memorial Sloan Kettering Cancer Center. “This is the reason why our research is important: to understand from the start which patients will require an intensified treatment plan and which patients, instead, can benefit from a lighter regimen will tremendously improve their management.”

Related Links:
MSK

New
Platinum Supplier
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
New
Gold Supplier
Procalcitonin Test
LIAISON B•R•A•H•M•S PCT II GEN
New
Scalable Loopamp System
HumaTurb
New
HE4 Assay
Human Epididymal Protein 4 (HE4) CLIA Kit

Print article
GLOBETECH PUBLISHING LLC

Channels

Clinical Chemistry

view channel
Image: The new assays are designed to run on the B•R•A•H•M•S KRYPTOR compact PLUS clinical chemistry analyzer (Photo courtesy of Thermo Fisher)

Breakthrough Immunoassays to Aid in Risk Assessment of Preeclampsia

Preeclampsia is a life-threatening blood pressure condition that can arise during pregnancy and the postpartum phase. This severe pregnancy complication is a primary cause of maternal and fetal mortality... Read more

Molecular Diagnostics

view channel
Image: The ClarityDX Prostate test can reduce unnecessary prostate biopsies by up to 35% (Photo courtesy of Nanostics)

Innovative Blood Test to Revolutionize Prostate Cancer Detection and Reduce Invasive Biopsies

One in six men will receive a prostate cancer diagnosis during their lives. Thankfully, if caught early, prostate cancer is highly treatable. However, the existing screening process has its limitations.... Read more

Hematology

view channel
Image: The latest FDA clearance has finally brought HemoScreen to its full potential as a true POC hematology analyzer (Photo courtesy of PixCell)

True POC Hematology Analyzer with Direct Capillary Sampling Enhances Ease-of-Use and Testing Throughput

An innovative 5-part differential Complete Blood Count (CBC) analyzer with direct capillary sampling capability significantly simplifies blood sampling and minimizes the pre-analytical process.... Read more

Microbiology

view channel
Image: On-chip pretreatment and rapid AST based directly on positive blood cultures (Photo courtesy of Liu Yang)

Integrated Solution for Rapid AST Directly From Positive Blood Cultures to Combat Bloodstream Infection

The presence of living bacteria in the bloodstream, known as bacteremia, can lead to serious conditions like bloodstream infections (BSIs) and sepsis, which can often be fatal. Quickly prescribing the... Read more

Pathology

view channel
Image: The Mitotic Counting algorithm was trained on over 100,000 individual mitosis and across seven scanner models (Photo courtesy of Gestalt Diagnostics)

New AI Algorithm for Use on Eight Types of Cancer Trained on Seven Scanner Models

A new artificial intelligence (AI) algorithm for use on one of the broadest trained environments is now available for commercial or research work. Gestalt Diagnostics (Spokane, WA, USA) has released the... Read more

Technology

view channel
Image: A new electrochemical device can quickly and inexpensively identify people at greatest risk for osteoporosis (Photo courtesy of ACS Central Science, 2023)

Electrochemical Device Identifies People at Higher Risk for Osteoporosis Using Single Blood Drop

With the global increase in life expectancy, the incidence of age-related conditions like osteoporosis is increasing. Osteoporosis, affecting around 200 million individuals worldwide, has a higher incidence... Read more

Industry

view channel
Image: AACC Middle East is a two-day conference that brings the latest in laboratory medicine to the Middle East region (Photo courtesy of ADLM)

AACC Middle East 2023 to Explore Latest Trends in Clinical Pathology and Laboratory Medicine

The AACC Middle East Conference and Exposition will be held by the Association for Diagnostics & Laboratory Medicine (ADLM - formerly AACC, Washington, DC, USA) in partnership with Life Dx (Abu Dhabi,... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.